Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 6
1950 10
1951 39
1952 31
1953 26
1954 18
1955 15
1956 10
1957 15
1958 7
1959 9
1960 15
1961 13
1962 10
1963 23
1964 30
1965 24
1966 15
1967 18
1968 25
1969 19
1970 24
1971 42
1972 30
1973 42
1974 27
1975 61
1976 54
1977 93
1978 81
1979 69
1980 66
1981 92
1982 103
1983 69
1984 82
1985 83
1986 91
1987 116
1988 140
1989 141
1990 180
1991 203
1992 242
1993 280
1994 236
1995 292
1996 265
1997 264
1998 263
1999 281
2000 283
2001 297
2002 324
2003 351
2004 384
2005 407
2006 375
2007 381
2008 421
2009 439
2010 482
2011 502
2012 529
2013 512
2014 524
2015 477
2016 436
2017 415
2018 467
2019 526
2020 585
2021 544
2022 430
2023 355
2024 385

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,154 results

Results by year

Filters applied: . Clear all
Page 1
Leucovorin (folinic acid) rescue for high-dose methotrexate: A review.
Jiang R, Mei S, Zhao Z. Jiang R, et al. J Clin Pharm Ther. 2022 Sep;47(9):1452-1460. doi: 10.1111/jcpt.13739. Epub 2022 Aug 5. J Clin Pharm Ther. 2022. PMID: 35929573 Review.
There are many strategies to overcome HDMTX-induced toxicities, such as hydration, alkalization, leucovorin rescue, and haemodialysis. Leucovorin rescue is a cornerstone for toxicity prevention in HDMTX treatment. However, the leucovorin dose adjustment and t …
There are many strategies to overcome HDMTX-induced toxicities, such as hydration, alkalization, leucovorin rescue, and haemodialysis …
Chronotherapy for cancer.
Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y. Eriguchi M, et al. Biomed Pharmacother. 2003 Oct;57 Suppl 1:92s-95s. doi: 10.1016/j.biopha.2003.08.012. Biomed Pharmacother. 2003. PMID: 14572683 Review.
The pharmacology of methotrexate.
Olsen EA. Olsen EA. J Am Acad Dermatol. 1991 Aug;25(2 Pt 1):306-18. doi: 10.1016/0190-9622(91)70199-c. J Am Acad Dermatol. 1991. PMID: 1918470 Review.
With the appropriate knowledge of the importance of urinary excretion of methotrexate and factors that influence this and with the ready availability of leucovorin, toxicity can be avoided in all but the most unusual of circumstances....
With the appropriate knowledge of the importance of urinary excretion of methotrexate and factors that influence this and with the ready ava …
Leucovorin.
Betcher DL, Burnham N. Betcher DL, et al. J Pediatr Oncol Nurs. 1989 Jul;6(3):102-4. J Pediatr Oncol Nurs. 1989. PMID: 2604922 No abstract available.
[Methotrexate].
Harten P. Harten P. Dtsch Med Wochenschr. 2001 May 18;126(20):610. doi: 10.1055/s-2001-14101-1. Dtsch Med Wochenschr. 2001. PMID: 11402932 German. No abstract available.
Levoleucovorin as replacement for leucovorin in cancer treatment.
Chuang VT, Suno M. Chuang VT, et al. Ann Pharmacother. 2012 Oct;46(10):1349-57. doi: 10.1345/aph.1Q677. Epub 2012 Oct 2. Ann Pharmacother. 2012. PMID: 23032661 Review.
DATA SYNTHESIS: From these pharmacokinetics and clinical studies, information on the use of levoleucovorin as a modulator of fluorouracil as well as when combined with other antitumor agents were scrutinized and extracted for comparison with leucovorin whenever possible. T …
DATA SYNTHESIS: From these pharmacokinetics and clinical studies, information on the use of levoleucovorin as a modulator of fluorouracil as …
Letter: Osteosarcoma--new hope.
Price CH. Price CH. Br Med J. 1975 Mar 22;1(5959):683. doi: 10.1136/bmj.1.5959.683-a. Br Med J. 1975. PMID: 1079156 Free PMC article. No abstract available.
Limitations of the PRODIGE 7 trial.
Ströhlein MA, Heiss MM. Ströhlein MA, et al. Lancet Oncol. 2021 May;22(5):e178. doi: 10.1016/S1470-2045(21)00134-0. Lancet Oncol. 2021. PMID: 33932376 No abstract available.
14,154 results
You have reached the last available page of results. Please see the User Guide for more information.